Sun Pharmaceutical Industries announced on Monday its acquisition of Checkpoint Therapeutics, a U.S.-based immunotherapy and targeted oncology firm, in a $355 million deal. The transaction aligns with Sun Pharma’s strategic expansion in oncology and immunotherapy, following its recent licensing agreement with Philogen for the anti-cancer drug Fibromun. The acquisition is Continue Reading
